2025年，药企已达成4起超百亿元收购！

制药网11-25

2025年，全球药企收购活动频发。其中，多家跨国巨头围绕弥补核心产品增长短板、补强细分赛道管线等原因，已展开了多笔超百亿元人民币的收购。默沙东92亿美元收购Cidara Therapeutics11月17日消息，默沙东宣布以92亿美元(约合654亿元人民币)现金收购Cidara Therapeutics，将其处于3期临床试验的主要资产流感预防药物CD388收入囊中。根据公开信息，在传统流感疫苗平均...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2586474490?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-11-25 10:28","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2586474490","market":"us","top_or_hot":-1,"title":"2025年，药企已达成4起超百亿元收购！","media":"制药网","content":"<div>\n<p>2025年，全球药企收购活动频发。其中，多家跨国巨头围绕弥补核心产品增长短板、补强细分赛道管线等原因，已展开了多笔超百亿元人民币的收购。默沙东92亿美元收购Cidara Therapeutics11月17日消息，默沙东宣布以92亿美元(约合654亿元人民币)现金收购Cidara Therapeutics，将其处于3期临床试验的主要资产流感预防药物CD388收入囊中。根据公开信息，在传统流感疫苗平均...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025112510331395189b86&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2025年，药企已达成4起超百亿元收购！</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2025年，药企已达成4起超百亿元收购！\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-11-25 10:28 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025112510331395189b86&s=b><strong>制药网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>2025年，全球药企收购活动频发。其中，多家跨国巨头围绕弥补核心产品增长短板、补强细分赛道管线等原因，已展开了多笔超百亿元人民币的收购。默沙东92亿美元收购Cidara Therapeutics11月17日消息，默沙东宣布以92亿美元(约合654亿元人民币)现金收购Cidara Therapeutics，将其处于3期临床试验的主要资产流感预防药物CD388收入囊中。根据公开信息，在传统流感疫苗平均...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025112510331395189b86&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0058720904.USD","symbol_name":"联博国际健康护理基金A","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025112510331395189b86&s=b","article_id":"2586474490","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025112510331395189b86&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2586474490","pubTimestamp":1764037735,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"2025年，全球药企收购活动频发。其中，多家跨国巨头围绕弥补核心产品增长短板、补强细分赛道管线等原因，已展开了多笔超百亿元人民币的收购。默沙东92亿美元收购Cidara Therapeutics11月17日消息，默沙东宣布以92亿美元现金收购Cidara Therapeutics，将其处于3期临床试验的主要资产流感预防药物CD388收入囊中。2024年6月，该药已获美国FDA批准上市，作为维持疗法治疗COPD成人患者。据悉，其此次收购旨在进一步扩大强生在实体瘤及前列腺癌治疗领域的业务版图。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0058720904.USD":"联博国际健康护理基金A","LU2430703178.SGD":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4H\" (SGDHDG) INC","BK4585":"ETF&股票定投概念","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","CNS":"科恩-斯蒂尔斯金融","LU0345770308.USD":"NINETY ONE GSF GLOBAL STRATEGIC EQUITY \"A\" (USD) ACC","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","BK4135":"资产管理与托管银行","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU0889566641.SGD":"FTSF - Templeton Shariah Global Equity A Acc SGD","LU1059921491.USD":"NORDEA 1 GLOBAL STABLE EQUITY \"HB\" (USDHDG) ACC","LU1674673691.USD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AD\" (USD) INC","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","SG9999002232.USD":"Allianz Global High Payout USD","IE00BVYPNV92.GBP":"GUINNESS GLOBAL EQUITY INCOME \"C\" (GBP) ACC","IE00BGHQF631.EUR":"GUINNESS GLOBAL EQUITY INCOME \"C\" (EUR) ACC","LU0234570918.USD":"高盛全球核心股票组合Acc Close","LU0985320562.USD":"NORDEA 1 GLOBAL STARS EQUITY \"BP\" (USD) ACC","BK4007":"制药","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","LU0070217475.USD":"JPM GLOBAL SELECT EQUITY \"A\" ACC","LU0912757837.SGD":"JPMorgan Investment Funds - Global Income A (mth) SGD-H","SG9999002224.SGD":"Allianz Global High Payout SGD","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU2592432038.USD":"WELLINGTON MULTI-ASSET HIGH INCOME \"A\" (USD) ACC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","JNJ":"强生","LU0795875086.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD","BK4532":"文艺复兴科技持仓","IE00B3T34201.USD":"BNY MELLON GLOBAL EQUITY INCOME \"B\" (USD) INC","IE00BN8TJ469.HKD":"FTGF CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A\" (HKD) INC","LU1244550494.USD":"FRANKLIN GLOBAL MULTI-ASSET INCOME \"A\" (USDHEDGED) ACC","LU0234572021.USD":"高盛美国核心股票组合Acc","LU0466842654.USD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"A\" (USD) ACC","LU1032466523.USD":"高盛全球多资产收益组合Acc","BK4581":"高盛持仓","IE00B7SZLL34.SGD":"Legg Mason ClearBridge - Value A Acc SGD-H","LU2129689514.USD":"FRANKLIN GLOBAL INCOME \"A\" (USD) INC","LU0345769128.USD":"NINETY ONE GSF GLOBAL EQUITY \"A\" (USD) ACC","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","LU1261432733.SGD":"Fidelity World A-ACC-SGD","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","LU1935042991.SGD":"MANULIFE GF GLOBAL MULTI-ASSET DIVERSIFIED INCOME  \"AA\" (SGDHDG) INC","LU2129689431.USD":"FRANKLIN GLOBAL INCOME \"A\" (USD) ACC","LU2430703095.HKD":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4\" (HKD) INC"},"translate_title":"In 2025, pharmaceutical companies have reached 4 acquisitions exceeding 10 billion yuan!","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JNJ":0.82,"CNS":1},"content_text":"2025年，全球药企收购活动频发。其中，多家跨国巨头围绕弥补核心产品增长短板、补强细分赛道管线等原因，已展开了多笔超百亿元人民币的收购。默沙东92亿美元收购Cidara Therapeutics11月17日消息，默沙东宣布以92亿美元(约合654亿元人民币)现金收购Cidara Therapeutics，将其处于3期临床试验的主要资产流感预防药物CD388收入囊中。根据公开信息，在传统流感疫苗平均预防效力仅为40%左右的背景下，CD388在2b期临床试验中最高剂量展现出76%的预防效力，且单次用药可提供长达4～5个月的保护。目前，Cidara正处于核心产品CD388数据验证的关键阶段，若能成功获批上市，将有望打开百亿美元级市场。默沙东100亿美元收购Verona Pharma7月9日，默沙东宣布以每股107美元全现金收购Verona Pharma，交易总额高达100亿美元。此次收购Verona Pharma，其旨在扩大其在心血管和肺部呼吸疾病治疗领域的管线和产品组合。公开资料显示，Verona Pharma是一家专注于呼吸系统疾病药物开发的生物制药公司，核心产品恩司芬群是一种磷酸二酯酶3/4(PDE3/4)双重抑制剂，具有支气管扩张和非甾体抗炎效果。该药物通过标准喷射雾化器直接进入肺部，无需复杂吸气流速配合。2024年6月，该药已获美国FDA批准上市，作为维持疗法治疗COPD成人患者。强生30.5亿美元收购Halda Therapeutics11月17日，强生宣布将以30.5亿美元现金(约人民币217亿元)收购肿瘤疗法研发公司Halda Therapeutics。据悉，其此次收购旨在进一步扩大强生在实体瘤及前列腺癌治疗领域的业务版图。Halda Therapeutics的核心候选药物HLD-0915目前处于早期至中期研发阶段，主要用于前列腺癌治疗。除核心管线外，该公司还布局了多款针对乳腺癌、肺癌及其他类型肿瘤的早期实验性疗法。交易达成后，Halda的研发资源与技术将融入强生体系，助力其在肿瘤治疗领域的创新突破与市场拓展。强生146亿美元收购Halda Therapeutics1月13日，强生宣布以146亿美元(合约1068.7亿人民币)收购神经类药物研发公司Intra-Cellular Therapies，持续推进在重点治疗领域的布局深化。据了解，Intra - Cellular Therapies 致力于开发针对中枢神经系统(CNS)疾病创新药物，核心资产聚焦精神疾病药物。核心产品是一款多靶点抗精神病药物CAPLYTA®(lumateperone)，这是目前美国FDA批准的头个用于治疗I型和II型双相抑郁症的辅助疗法及单一疗法，同时亦获准用于治疗成人精神分裂症。通过此次收购，强生将借助对方的创新药物拓展该细分市场，进一步完善自身在慢病与专科疾病领域的布局。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"merge","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2586474490","isCrawlerRequest":true}